MikosA., and JohnsonP.C.Editorial: redefining tissue engineering and our new rapid publication policy. Tissue Eng, 12, 1, 2006.
6.
JohnsonP.C., BertramT.A., TawilB., and HellmanK.B.Hurdles in tissue engineering/regenerative medicine commercialization: a survey of North American academia and industry. Tissue Eng Part A, 17, 5, 2011.
7.
HellmanK.B., JohnsonP.C., BertramT.A., and TawilB.Challenges in tissue engineering and regenerative medicine product commercialization: building an industry. Tissue Eng Part A, 17, 1, 2011.
8.
BertramT.A., TentoffE., JohnsonP.C., TawilB., Van DykeM., and HellmanK.B.Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry. Tissue Eng Part A, 18, 2187, 2012.
9.
BertramT.A., JohnsonP.C., TawilB., Van DykeM., and HellmanK.B.Enhancing tissue engineering/regenerative medical product commercialization: the role of science in regulatory decision making for tissue Engineering/regenerative medicine product development. Tissue Eng Part A, 19, 2313, 2013.
10.
RahmanyM.B., TawilB.J., HellmanK.B., JohnsonP.C., Van DykeM., and BertramT.Bench to business: a framework to assess technology readiness. Tissue Eng Part A, 19, 21, 2013.
11.
JohnsonP., BertramT., HellmanK., TawilB., Van DykeM., and CartyN.Awareness of the role of science in the FDA regulatory submission process: a survey of the TERMIS-Americas membership. Tissue Eng Part A, 20, 1565, 2014.